Online inquiry

IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12380MR)

This product GTTS-WQ12380MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SAA1 gene. The antibody can be applied in AA amyloidosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000331.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6288
UniProt ID P0DJI8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12380MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5100MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ4306MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ12590MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ14635MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ15731MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ10564MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ15619MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ4801MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW